Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Movement Disorders

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.25175PMID 23079770PMCID PMC3481179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fundamentals of Clinical Trials

  2012cited by this paper
• A randomized recruitment intervention trial in Parkinson’s disease to increase participant diversity: early stopping for lack of efficacy

  2012cited by this paper
• CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

  2010cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  2009cited by this paper
• Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

  2009cited by this paper
• Levodopa response in early Parkinson's disease

  2009cited by this paper
• Using global statistical tests in long‐term Parkinson's disease clinical trials

  2009cited by this paper
• Minority enrollment in Parkinson's disease clinical trials.

  2009cited by this paper
• A rank‐based sample size method for multiple outcomes in clinical trials

  2008cited by this paper
• A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results

  2008cited by this paper
• The Use of a Global Statistical Approach for the Design and Data Analysis of Clinical Trials with Multiple Primary Outcomes

  2008cited by this paper
• Pharmacokinetics of creatine.

  2007cited by this paper
• A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

  2007cited by this paper
• Normative Symbol Digit Modalities Test performance in a community-based sample.

  2006cited by this paper
• A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

  2006cited by this paper
• Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials

  2005cited by this paper
• Adjusting O'Brien's Test to Control Type I Error for the Generalized Nonparametric Behrens–Fisher Problem

  2005cited by this paper
• Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment

  2004cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

  2004cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

  2004cited by this paper
• Neuroprotective agents for clinical trials in Parkinson’s disease

  2003cited by this paper
• Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

  2003cited by this paper
• Cross-cultural evaluation of the Parkinson's Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain.

  2003cited by this paper
• Assessment of cognition in Parkinson’s disease

  2003cited by this paper
• A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

  2002cited by this paper
• Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease

  2002cited by this paper
• Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders

  2001cited by this paper
• Ten-year follow-up of three different initial treatments in de-novo PD

  2001cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study.

  2000cited by this paper
• Oxidative stress and genetics in the pathogenesis of Parkinson's disease.

  2000cited by this paper
• Creatine and cyclocreatine attenuate MPTP neurotoxicity.

  1999cited by this paper
• Immediate-release and controlled-release carbidopa/levodopa in PD

  1999cited by this paper
• Implications of the 5-year CR FIRST trial

  1998cited by this paper
• Creatine: a review of its nutritional applications in sport.

  1998cited by this paper
• The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality

  1998cited by this paper
• Creatine supplementation and exercise performance: an update.

  1998cited by this paper
• Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

  1996cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.

  1996cited by this paper
• Epidemiologic observations on Parkinson's disease

  1996cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

  1996cited by this paper
• The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993.

  1995cited by this paper
• Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance.

  1995cited by this paper
• The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease

  1994cited by this paper
• New insights into the cause of Parkinson's disease

  1992cited by this paper
• EuroQol--a new facility for the measurement of health-related quality of life.

  1990cited by this paper
• EuroQol : a new facility for the measurement of health-related quality of life

  1990cited by this paper
• Interobserver agreement for the assessment of handicap in stroke patients.

  1989cited by this paper
• Interobserver agreement for the assessment of handicap in stroke patients.

  1988cited by this paper
• Procedures for comparing samples with multiple endpoints.

  1984cited by this paper
• Projection technique for evaluating surgery in Parkinson’s disease

  1969cited by this paper

• Oxyphylla A exerts antiparkinsonian effects by ameliorating 6-OHDA-induced mitochondrial dysfunction and dyskinesia in vitro and in vivo.

  2024cites this paper
• Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression

  2023cites this paper
• Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression

  2023cites this paper
• Association of women-specific health factors in the severity of Parkinson’s disease

  2022cites this paper
• Semiparametric regression modeling of the global percentile outcome.

  2022cites this paper
• Neuroprotective Potential of Creatine. Hidden Resources of Its Therapeutic and Preventive Use

  2022cites this paper
• Parkinson's disease in Women: Mechanisms underlying sex differences.

  2021cites this paper
• Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum.

  2021cites this paper
• Progress towards therapies for disease modification in Parkinson's disease.

  2021cites this paper
• Isradipine Versus Placebo in Early Parkinson Disease

  2020cites this paper
• GenoPheno: cataloging large-scale phenotypic and next-generation sequencing data within human datasets

  2020cites this paper
• A new mixed‐effects mixture model for constrained longitudinal data

  2019cites this paper
• The Assessment of Cognition in Translational Medicine: A Contrast Between the Approaches Used in Alzheimer's Disease and Major Depressive Disorder

  2019cites this paper
• Huntington's disease: Current and future therapeutic prospects

  2018cites this paper
• Bayesian hierarchical joint modeling using skew-normal/independent distributions

  2018cites this paper
• Autonomic and electrocardiographic findings in Parkinson's disease.

  2017cites this paper
• A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)

  2017cites this paper
• Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

  2017cites this paper
• Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores

  2017cites this paper
• Bayesian multivariate augmented Beta rectangular regression models for patient-reported outcomes and survival data

  2017cites this paper
• Robust Bayesian Hierarchical Model Using Monte-Carlo Simulation

  2017cites this paper
• Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.

  2017cites this paper
• Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort

  2017cites this paper
• Mitochondrial Therapeutic Approaches in Parkinson’s Disease

  2016cites this paper
• Beyond muscles: The untapped potential of creatine.

  2016cites this paper
• 25+ Observations Over 25+ Years for Surviving and Thriving in the Dietary Supplement Quality Control and/or Perception Versus Reality World

  2016cites this paper
• Robust Bayesian hierarchical model using normal/independent distributions

  2016cites this paper
• Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.

  2016cites this paper
• Communicating with participants during the conduct of multi-center clinical trials

  2016cites this paper
• Augmented Beta rectangular regression models: A Bayesian perspective

  2016cites this paper
• Parkinson’s Disease and Aging

  2016cites this paper
• A review of disease progression models of Parkinson's disease and applications in clinical trials

  2016cites this paper
• Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1

  2016cites this paper
• Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.

  2016cites this paper
• Influence of Dietary Constituents on Motor and Non-motor Symptoms in Parkinson’s Disease

  2015cites this paper
• The ongoing pursuit of neuroprotective therapies in Parkinson disease

  2015cites this paper
• How to optimize the treatment of early stage Parkinson’s disease

  2015cites this paper
• The ongoing pursuit of neuroprotection in Parkinson ’ s disease

  2015cites this paper
• Delineating nonmotor symptoms in early Parkinson's disease and first‐degree relatives

  2015cites this paper
• The Effect of Creatine and Coenzyme Q10 Combination Therapy on Mild Cognitive Impairment in Parkinson's Disease

  2015cites this paper
• Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine

  2015cites this paper
• Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 Cohort

  2015cites this paper
• The futility study--Progress over the last decade.

  2015cites this paper
• Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

  2015cites this paper
• Validation of an Ambulatory Capacity Measure in Parkinson Disease: A Construct Derived from the Unified Parkinson's Disease Rating Scale

  2015cites this paper
• Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease

  2015cites this paper
• Parkinson's disease severity and use of dopaminergic medications.

  2015cites this paper
• Sex Differences in Clinical Features of Early, Treated Parkinson’s Disease

  2015influential citation
• Polymersome Mediated Delivery of Mitochondrial therapeutics to parkin Mutant Fibroblasts

  2015cites this paper
• Mitochondrial dysfunction in response to neurotoxins and the role of mitophagy

  2014cites this paper
• Nutrition and Gastrointestinal Health as Modulators of Parkinson’s Disease

  2014cites this paper
• Creatine for Parkinson's disease.

  2014cites this paper
• Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease

  2014cites this paper
• Cervical spinal cord injury: tailoring clinical trial endpoints to reflect meaningful functional improvements

  2014cites this paper
• The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort.

  2014cites this paper
• Malignant melanoma in early‐treated Parkinson's disease: The NET‐PD trial

  2014cites this paper
• The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease

  2014cites this paper
• Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

  2014cites this paper
• No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial

  2014influential citation
• Pharma-Nutrition

  2014influential citation
• Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.

  2013cites this paper
• Exenatide as a novel treatment for Parkinson's Disease

  2013cites this paper
• Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

  2013cites this paper
• The Role of Oxidative Stress in Parkinson's Disease

  2013cites this paper
• Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease

  2013cites this paper
• Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

  2013cites this paper
• Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease

  2013cites this paper
• Digital Commons @ University of South Florida Digital Commons @ University of South Florida

  year unknowncites this paper